<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335426">
  <stage>Registered</stage>
  <submitdate>28/04/2010</submitdate>
  <approvaldate>6/05/2010</approvaldate>
  <actrnumber>ACTRN12610000359033</actrnumber>
  <trial_identification>
    <studytitle>Clinical trial of Angipars in patients with pulmonary hypertension.</studytitle>
    <scientifictitle>Phase II clinical trial of oral form Angipars on quality of life and pulmonary artery pressure in patients with primary pulmonary hypertension without control group.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Adminstration of oral form of Angipars(Semeli)containing 100 mg active ingredient, three times a day for six months.</interventions>
    <comparator>No Control Group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>6 minute walking distance. This is the distance that patintt can walk in 6 minutes and is thr primary outcome itself.</outcome>
      <timepoint>At the Start of treatment, 3rd, 6th and 9th month.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pulmonary artery pressure measured by echocardiography.</outcome>
      <timepoint>At the Start of treatment, 3rd, 6th and 9th month.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>World Health Organization (WHO) Functional class.</outcome>
      <timepoint>Baseline then Monthly for 9 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dyspnea(Borg) quality of life</outcome>
      <timepoint>Baseline then Monthly for 9 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Primary pulmonary hypertension.
Stable functional class II more than 4 months.
Six Minuth Walking Distance(6MWD) between 150-425 meters.
Forced Expiratory Volume during one second(FEV1)&gt;40% and pulmonary artery pressure more than 25 mmHg at rest or 30 during activity.
FEV1&lt;25% that do not respond to full dose anti infammatory or bronchodilators.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unstable cardiopulmonary condition in last three months.
6MWD less than 150 meters.
Diastolic blood pressure less than 85 mmHg.
Bosentan or Prostanoid intake during 3 months before Entering study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/06/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Tehran</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pars Roos Biotechnology Co.</primarysponsorname>
    <primarysponsoraddress>No.568, 13th Alley, Hormozan st., Shahrak gharb, Tehran,14678, Iran</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Dr. Haleh Hamedifar</fundingname>
      <fundingaddress>No.3, First Alley, Kharazm Avenue, Shahrak gharb, Tehran,14678, Iran</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Shariaty Hospital</sponsorname>
      <sponsoraddress>Shariaty Hospital, North Kargar st., Tehran,14114, Iran</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>According to basic science research result, Angipars(Semeli) has anti fibrosis effect and postive effect for perfusion. Therer are a few drug can help the patients with Pulomonary hypertension. We decided to evaluate the safety and efficacy of this drug for pulmonary hypertension.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Digestive Disease Research Center Ethic Committee</ethicname>
      <ethicaddress>Digestive Disease Research Center, Shariaty hospital, North Kargar st., Tehran,14114, Iran</ethicaddress>
      <ethicapprovaldate>17/03/2010</ethicapprovaldate>
      <hrec>416/102</hrec>
      <ethicsubmitdate>18/01/2010</ethicsubmitdate>
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Omolbanin Paknejad</name>
      <address>Shariaty Hospital, North kargar st., Tehran, 14114, Iran</address>
      <phone>00982184901</phone>
      <fax>00982188633039</fax>
      <email>opaknjd@ut.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Omolbanin Paknejad</name>
      <address>Shariaty Hospital, North kargar st., Tehran, 14114, Iran</address>
      <phone>00982184901</phone>
      <fax>00982188633039</fax>
      <email>opaknjd@ut.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Omolbanin Paknejad</name>
      <address>Shariaty Hospital, North kargar st., Tehran, 14114, Iran</address>
      <phone>00982184901</phone>
      <fax>00982188633039</fax>
      <email>opaknjd@ut.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>